Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment

Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment

The profound but frequently transient clinical responses to BRAFV600 inhibitor (BRAFi) treatment in melanoma emphasize the need for combinatorial therapies. Multiple clinical trials combining BRAFi and immunotherapy are under way to further enhance therapeutic responses. However, to which extent BRA...

Full description

Bibliographic Details
Main Authors: Natalia Pieper, Anne Zaremba, Sonia Leonardelli, Franziska Noelle Harbers, Marion Schwamborn, Silke Lübcke, Barbara Schrörs, Jolanthe Baingo, Alexander Schramm, Sebastian Haferkamp, Ulrike Seifert, Antje Sucker, Volker Lennerz, Thomas Wölfel, Dirk Schadendorf, Bastian Schilling, Annette Paschen, Fang Zhao
Format: Article
Language:English
Published: Taylor & Francis Group 2018-08-01
Series:OncoImmunology
Subjects:
braf
cd8+ t cells
mek
antigens
inhibitor
melanoma
resistance
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1450127

Internet

http://dx.doi.org/10.1080/2162402X.2018.1450127

Similar Items